Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/31 05:58:45 pm
56.23 USD   -0.44%
05/27 MERCK : Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir..
05/26 MERCK : Corporate Social Responsibility Related News Releases and St..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:03am CEST
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable.

Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable.

Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said.

A Mylan spokeswoman couldn't immediately be reached.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
05/27 MERCK & CO., INC. : Submission of Matters to a Vote of Security Holders (form 8-..
05/27 MERCK : Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazopr..
05/26 MERCK : Corporate Social Responsibility Related News Releases and Story Ideas fo..
05/24 MERCK : Announces Third-Quarter 2016 Dividend
05/24 MERCK : to Present at the UBS Global Healthcare Conference
05/24 MSD ANIMAL HEALTH : Receives Marketing Approval from European Medicines Agency f..
05/24 MERCK : Announces FDA Accepts Samsung Bioepis’ Biologics License Applicati..
05/23 MERCK : Foundation Announces the Alliance to Advance Patient-Centered Cancer Car..
05/23DJGermany's Bayer Offers $62 Billion in Cash for Monsanto
05/19DJGermany's Bayer Breaks With Caution in Monsanto Bid
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials